| Literature DB >> 16507459 |
Robert K D Peterson1, Paula A Macedo, Ryan S Davis.
Abstract
West Nile virus (WNV) has been a major public health concern in North America since 1999, when the first outbreak in the Western Hemisphere occurred in New York City. As a result of this ongoing disease outbreak, management of mosquitoes that vector WNV throughout the United States and Canada has necessitated using insecticides in areas where they traditionally have not been used or have been used less frequently. This has resulted in concerns by the public about the risks from insecticide use. The objective of this study was to use reasonable worst-case risk assessment methodologies to evaluate human-health risks for WNV and the insecticides most commonly used to control adult mosquitoes. We evaluated documented health effects from WNV infection and determined potential population risks based on reported frequencies. We determined potential acute (1-day) and subchronic (90-day) multiroute residential exposures from each insecticide for several human subgroups during a WNV disease outbreak scenario. We then compared potential insecticide exposures to toxicologic and regulatory effect levels. Risk quotients (RQs, the ratio of exposure to toxicologic effect) were < 1.0 for all subgroups. Acute RQs ranged from 0.0004 to 0.4726, and subchronic RQs ranged from 0.00014 to 0.2074. Results from our risk assessment and the current weight of scientific evidence indicate that human-health risks from residential exposure to mosquito insecticides are low and are not likely to exceed levels of concern. Further, our results indicate that, based on human-health criteria, the risks from WNV exceed the risks from exposure to mosquito insecticides.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16507459 PMCID: PMC1392230 DOI: 10.1289/ehp.8667
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Toxicologic effects and regulatory end points for the active ingredients.
| Acute
| Subchronic
| |||
|---|---|---|---|---|
| Compound | End point | Study and toxicologic effects | End point | Study and toxicologic effects |
| Malathion | NOAEL = 50 mg/kg/day | Based on reduction in maternal bw gain in a study with pregnant rabbits | NOAEL = 2.4 mg/kg/day | Based on inhibition of blood enzyme activity at 50 ppm malathion in the diet in a 24-month study in rats |
| Naled | NOAEL = 1.0 mg/kg/day | Based on inhibition of blood and brain enzymes in a 28-day study in rats | NOAEL = 1.0 mg/kg/day | Based on inhibition of blood and brain enzymes in a 28-day study in rats |
| Permethrin | NOAEL = 25 mg/kg/day | Acute neurotoxicity study in rats
| NOAEL = 25 mg/kg/day | Acute neurotoxicity study in rats
|
| Resmethrin | NOEL = 10 mg/kg/day | Based on liver weight increases in a 6-month study in dogs | NOEL = 10 mg/kg/day | Based on liver weight increases in a 6-month study in dogs |
| Phenothrin | NOEL = 70 mg/kg/day | 13-week study in rats
| NOEL = 70 mg/kg/day | 13-week study in rats
|
| Pyrethrins | NOAEL = 20 mg/kg/day | Acute neurotoxicity study in rats
| NOAEL = 4.37 mg/kg/day | Rat chronic toxicity study
|
| Piperonyl butoxide | NOAEL = 630 mg/kg/day | Developmental toxicity study in rats
| NOAEL = 89 mg/kg/day | Two generation reproduction study in rats
|
Abbreviations: bw, body weight; LOAEL, lowest observed adverse effect level. LOEL, lowest observed effect level; NOEL, no observed effect level; UF, uncertainty factor used to determine the RfD.
U.S. EPA 2000c.
U.S. EPA 2002a.
U.S. EPA 2005c.
U.S. EPA 2000a.
U.S. EPA 2000b.
U.S. EPA 2005b.
U.S. EPA 2005a.
Application rates, chemical properties, and predicted environmental concentrations of active ingredients.
| Active ingredient
| |||||||
|---|---|---|---|---|---|---|---|
| Property | Piperonyl butoxide | Phenothrin | Permethrin | Resmethrin | Malathion | Naled | Pyrethrins |
| Application rate (kg ai/ha) | 0.0392 | 0.004 | 0.0078 | 0.0078 | 0.0639 | 0.0224 | 0.009 |
| Density (g/mL) | 0.898 | 0.898 | 0.8657 | 0.87 | 1.23 | 1.67 | 0.81 |
| Surface photolysis half-life (days) | NA | 6 | 23 | 0.14 | 6.5 | 2.4 | 0.5 |
| Soil aerobic half-life (days) | 14 | 7 | 37 | 30 | 1 | 1 | 1 |
| Acute air concentration (μg/m3) | 7.39 | 0.81 | 1.55 | 1.61 | 9.76 | 1.68 | 1.7 |
| 1-Day acute produce concentration (mg/kg dry wt) | 0.525 | 0.054 | 0.105 | 0.105 | 0.855 | 0.3 | 0.12 |
| 90-Day mean surface concentration (mg/m2) | 15.42 | 0.43 | 4.14 | 0.22 | 2.18 | 0.65 | 0.54 |
| 90-Day mean produce concentration (mg/kg dry wt) | 2.88 | 0.055 | 0.096 | 0.012 | 0.73 | 0.13 | 0.21 |
Abbreviations: ai/ha, active ingredient per hectare; NA, not available; wt, weight.
Clarke Mosquito Control Products (1999b).
Clarke Mosquito Control Products (1999a).
Bayer Environmental Science (2004).
Griffin (2001).
AMVAC (2003).
McLaughlin Gormley King Co. (2004).
Surface and produce concentrations determined from soil aerobic half-life only.
U.S. Department of Agriculture (USDA 2005).
NYCDOH (2001).
Food and Agricultural Organization (2000).
U.S. EPA (2005c).
6-Hr mean concentration at 7.6 m from spray source.
90-Day mean surface concentration within 91.4 m of the spray source.
Acute RQs for the active ingredients for each subgroup.a
| Subgroup | Malathion | Naled | Permethrin | Resmethrin | Phenothrin | Pyrethrins | Piperonyl butoxide |
|---|---|---|---|---|---|---|---|
| Adult males | 0.0076 | 0.1496 | 0.0020 | 0.0052 | 0.0004 | 0.0081 | 0.0004 |
| Adult females | 0.0079 | 0.1576 | 0.0021 | 0.0055 | 0.0004 | 0.0085 | 0.0004 |
| Children (10–12 years) | 0.0105 | 0.2123 | 0.0029 | 0.0072 | 0.0006 | 0.0113 | 0.0006 |
| Children (5–6 years) | 0.0177 | 0.3631 | 0.0049 | 0.0123 | 0.0010 | 0.0190 | 0.0009 |
| Toddlers (2–3 years) | 0.0225 | 0.4726 | 0.0063 | 0.0159 | 0.0013 | 0.0245 | 0.0012 |
| Infants (0.5–1.5 years) | 0.0188 | 0.4495 | 0.0058 | 0.0147 | 0.0012 | 0.0218 | 0.0010 |
RQ = total acute PE ÷ RfD.
Subchronic RQs for the adulticides for each subgroup.a
| Subgroup | Malathion | Naled | Permethrin | Resmethrin | Phenothrin | Pyrethrins | Piperonyl butoxide |
|---|---|---|---|---|---|---|---|
| Adult males | 0.0360 | 0.0259 | 0.0007 | 0.0004 | 0.0001 | 0.0056 | 0.0032 |
| Adult females | 0.0363 | 0.0269 | 0.0007 | 0.0004 | 0.0001 | 0.0056 | 0.0032 |
| Children (10–12 years) | 0.0470 | 0.0290 | 0.0008 | 0.0005 | 0.0001 | 0.0074 | 0.0043 |
| Children (5–6 years) | 0.0676 | 0.0447 | 0.0012 | 0.0009 | 0.0002 | 0.0104 | 0.0059 |
| Toddlers (2–3 years) | 0.1815 | 0.1294 | 0.0204 | 0.0037 | 0.0009 | 0.0270 | 0.0262 |
| Infants (0.5–1.5 years) | 0.2074 | 0.1661 | 0.0301 | 0.0054 | 0.0013 | 0.0292 | 0.0325 |
RQ = total subchronic PE ÷ RfD.